US · Healthcare · Drug Manufacturers - General
EPS came in at 1.36 against a street estimate of 1.27 — a beat of 7.1%.
Analysts rate GlaxoSmithKline PLC ADR a hold (1 buy, 5 hold, 2 sell out of 8) with an average price target of $59.33.
CONFIDENT GSK reported Q2 sales +5% to £8.4B with strong specialty/vaccine growth offsetting generic pressure. Launched £1.9B cost-cutting program to fund 20+ Phase III trials. Raised FY26 sales/operating profit guidance; lowered EPS due to Nuvalent acquisition debt. Q2 2026 U.S. acceleration in HIV market share; China driving Nucala COPD growth with majority bio-naive share. Europe benefits from Shingrix, Blenrep gaining reimbursement (Germany, Spain). Analysts pressed asset acceleration criteria, confidence in small cohorts (Nela), and GenMed softness. Management anchored to data, validated targets, and competitive benchmarking; acknowledged CALM-2 miss but defended portfolio breadth and execution discipline. 2026-07-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 3.38% |
| Dodge & Cox | 2.41% |
| Fisher Asset Management, LLC | 1.78% |
| PRIMECAP Management Company | 1.26% |
| Acadian Asset Management LLC | 0.59% |
| Wellington Management Company LLP | 0.57% |
| Morgan Stanley - Brokerage Accounts | 0.55% |
| The Goldman Sachs Group Inc | 0.48% |
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.45 / share ex-date Aug 14, 2026 · pay Oct 8, 2026 | 2026-08-14 |
| Dividend | $0.46 / share ex-date May 15, 2026 · pay Jul 9, 2026 | 2026-05-15 |
| Dividend | $0.49 / share ex-date Feb 20, 2026 · pay Apr 9, 2026 | 2026-02-20 |
| Dividend | $0.42 / share ex-date Nov 14, 2025 · pay Jan 8, 2026 | 2025-11-14 |
| Dividend | $0.43 / share ex-date Aug 15, 2025 · pay Oct 9, 2025 | 2025-08-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GlaxoSmithKline PLC ADR — free to start.
Google PlayApp StoreData updated 2026-09-18.